Cargando…

The pulmonary route as a way to drug repositioning in COVID-19 therapy

INTRODUCTION: The outbreak of the disease caused by the new coronavirus (COVID-19) has been affecting society's routine and its patterns of interaction worldwide, in addition to the impact on the global economy. To date, there is still no clinically effective treatment for this comorbidity, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarcinelli, Michelle Alvares, Martins da Silva, Thalita, Artico Silva, Andressa Daniele, Ferreira de Carvalho Patricio, Beatriz, Mendes de Paiva, Flávia Costa, Santos de Lima, Raissa, Leal da Silva, Manuela, Antunes Rocha, Helvécio Vinícius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903910/
https://www.ncbi.nlm.nih.gov/pubmed/33649708
http://dx.doi.org/10.1016/j.jddst.2021.102430
_version_ 1783654826398187520
author Sarcinelli, Michelle Alvares
Martins da Silva, Thalita
Artico Silva, Andressa Daniele
Ferreira de Carvalho Patricio, Beatriz
Mendes de Paiva, Flávia Costa
Santos de Lima, Raissa
Leal da Silva, Manuela
Antunes Rocha, Helvécio Vinícius
author_facet Sarcinelli, Michelle Alvares
Martins da Silva, Thalita
Artico Silva, Andressa Daniele
Ferreira de Carvalho Patricio, Beatriz
Mendes de Paiva, Flávia Costa
Santos de Lima, Raissa
Leal da Silva, Manuela
Antunes Rocha, Helvécio Vinícius
author_sort Sarcinelli, Michelle Alvares
collection PubMed
description INTRODUCTION: The outbreak of the disease caused by the new coronavirus (COVID-19) has been affecting society's routine and its patterns of interaction worldwide, in addition to the impact on the global economy. To date, there is still no clinically effective treatment for this comorbidity, and drug repositioning might be a good strategy considering the established clinical safety profile. In this context, since COVID-19 affects the respiratory tract, a promising approach would be the pulmonary drug delivery. OBJECTIVE: Identify repurposing drug candidates for the treatment of COVID-19 based on the data of ongoing clinical trials and in silico studies and also assess their potential to be applied in formulations for pulmonary administration. METHOD: A integrative literature review was conducted between June and July 2020, by extracting the results from Clinical Trials, PubMed, Web of Science and Science Direct databases. RESULTS: By crossing the results obtained from diverse sources, 21 common drugs were found, from which only 4 drugs presented studies of pulmonary release formulations, demonstrating the need for greater investment and incentive in this field. CONCLUSION: Even though the lung is a target that facilitates viral infection and replication, formulations for pulmonary delivery of suitable drugs are still lacking for COVID-19 treatment. However, it is indisputable that the pandemic constitutes a concrete demand, with a profound impact on public health, and that, with the appropriate investments, it will give the pharmaceutical industry an opportunity to reinforce the pulmonary delivery field.
format Online
Article
Text
id pubmed-7903910
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-79039102021-02-25 The pulmonary route as a way to drug repositioning in COVID-19 therapy Sarcinelli, Michelle Alvares Martins da Silva, Thalita Artico Silva, Andressa Daniele Ferreira de Carvalho Patricio, Beatriz Mendes de Paiva, Flávia Costa Santos de Lima, Raissa Leal da Silva, Manuela Antunes Rocha, Helvécio Vinícius J Drug Deliv Sci Technol Review Article INTRODUCTION: The outbreak of the disease caused by the new coronavirus (COVID-19) has been affecting society's routine and its patterns of interaction worldwide, in addition to the impact on the global economy. To date, there is still no clinically effective treatment for this comorbidity, and drug repositioning might be a good strategy considering the established clinical safety profile. In this context, since COVID-19 affects the respiratory tract, a promising approach would be the pulmonary drug delivery. OBJECTIVE: Identify repurposing drug candidates for the treatment of COVID-19 based on the data of ongoing clinical trials and in silico studies and also assess their potential to be applied in formulations for pulmonary administration. METHOD: A integrative literature review was conducted between June and July 2020, by extracting the results from Clinical Trials, PubMed, Web of Science and Science Direct databases. RESULTS: By crossing the results obtained from diverse sources, 21 common drugs were found, from which only 4 drugs presented studies of pulmonary release formulations, demonstrating the need for greater investment and incentive in this field. CONCLUSION: Even though the lung is a target that facilitates viral infection and replication, formulations for pulmonary delivery of suitable drugs are still lacking for COVID-19 treatment. However, it is indisputable that the pandemic constitutes a concrete demand, with a profound impact on public health, and that, with the appropriate investments, it will give the pharmaceutical industry an opportunity to reinforce the pulmonary delivery field. Elsevier B.V. 2021-06 2021-02-24 /pmc/articles/PMC7903910/ /pubmed/33649708 http://dx.doi.org/10.1016/j.jddst.2021.102430 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Sarcinelli, Michelle Alvares
Martins da Silva, Thalita
Artico Silva, Andressa Daniele
Ferreira de Carvalho Patricio, Beatriz
Mendes de Paiva, Flávia Costa
Santos de Lima, Raissa
Leal da Silva, Manuela
Antunes Rocha, Helvécio Vinícius
The pulmonary route as a way to drug repositioning in COVID-19 therapy
title The pulmonary route as a way to drug repositioning in COVID-19 therapy
title_full The pulmonary route as a way to drug repositioning in COVID-19 therapy
title_fullStr The pulmonary route as a way to drug repositioning in COVID-19 therapy
title_full_unstemmed The pulmonary route as a way to drug repositioning in COVID-19 therapy
title_short The pulmonary route as a way to drug repositioning in COVID-19 therapy
title_sort pulmonary route as a way to drug repositioning in covid-19 therapy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903910/
https://www.ncbi.nlm.nih.gov/pubmed/33649708
http://dx.doi.org/10.1016/j.jddst.2021.102430
work_keys_str_mv AT sarcinellimichellealvares thepulmonaryrouteasawaytodrugrepositioningincovid19therapy
AT martinsdasilvathalita thepulmonaryrouteasawaytodrugrepositioningincovid19therapy
AT articosilvaandressadaniele thepulmonaryrouteasawaytodrugrepositioningincovid19therapy
AT ferreiradecarvalhopatriciobeatriz thepulmonaryrouteasawaytodrugrepositioningincovid19therapy
AT mendesdepaivaflaviacosta thepulmonaryrouteasawaytodrugrepositioningincovid19therapy
AT santosdelimaraissa thepulmonaryrouteasawaytodrugrepositioningincovid19therapy
AT lealdasilvamanuela thepulmonaryrouteasawaytodrugrepositioningincovid19therapy
AT antunesrochahelveciovinicius thepulmonaryrouteasawaytodrugrepositioningincovid19therapy
AT sarcinellimichellealvares pulmonaryrouteasawaytodrugrepositioningincovid19therapy
AT martinsdasilvathalita pulmonaryrouteasawaytodrugrepositioningincovid19therapy
AT articosilvaandressadaniele pulmonaryrouteasawaytodrugrepositioningincovid19therapy
AT ferreiradecarvalhopatriciobeatriz pulmonaryrouteasawaytodrugrepositioningincovid19therapy
AT mendesdepaivaflaviacosta pulmonaryrouteasawaytodrugrepositioningincovid19therapy
AT santosdelimaraissa pulmonaryrouteasawaytodrugrepositioningincovid19therapy
AT lealdasilvamanuela pulmonaryrouteasawaytodrugrepositioningincovid19therapy
AT antunesrochahelveciovinicius pulmonaryrouteasawaytodrugrepositioningincovid19therapy